Abstract The prevalence of antibiotic resistance and their genetic determinants in colonizing group B streptococci (GBS) sampled in a Swedish nationwide survey was examined. In five GBS isolates (1.3%), kanamycin/amikacin resistance and the presence of the aphA-3 gene was identified. Three of these isolates carried the aad-6 gene and were streptomycin-resistant. Screening with kanamycin and streptomycin 1,000-μg disks enabled a rapid and easy detection of these isolates. In all, 312/396 (79%) GBS were tetracycline-resistant and 95% of the examined isolates harbored the tetM gene. Among the 22 (5.5%) GBS resistant to erythromycin and/or clindamycin, the ermB gene was detected in nine isolates (41%) and erm(A/TR) in ten isolates (45%). A high level of erythromycin and clindamycin resistance with minimum inhibitory concentrations (MICs) >256 mg/L was found in four serotype V isolates that harbored ermB. The erythromycin/clindamycin resistance was distributed among all of the common serotypes Ia, Ib, II,
Introduction
Group B streptococci (GBS) are recognized as a common cause of life-threatening infections in neonates. When the mother carries GBS in the vagina and/or rectum, generally an asymptomatic condition, the infant is exposed to the bacteria during the passage in the birth canal. In an attempt to prevent GBS infection in neonates, most western countries have introduced programs for intrapartum antibiotic prophylaxis (IAP) [1, 2] . The use of IAP has drastically reduced neonatal invasive GBS infections during the first week of life [1, 3] . However, the increased use of antibiotics to women in labor has raised concerns about the development of antibiotic resistance. For effective treatment and IAP, it is important to monitor the prevalence of antibiotic resistance in GBS over time. Intravenous penicillin G is a first-choice drug for IAP and is given either to GBS-colonized women or to women considered to be at risk. For the treatment of established infections, penicillin or ampicillin is often used in combination with an aminoglycoside such as gentamicin [4] . Streptococci are intrinsically resistant to aminoglycosides and are not treatable with aminoglycosides given as a single therapy. However, the combination of a cell-wall active antibiotic such as penicillin or ampicillin and gentamicin has been shown to enhance the killing of GBS [5] . The synergistic effect between beta-lactam antibiotics and aminoglycosides is abolished if the isolate is high-level gentamicin-resistant, a resistance mechanism best described in enterococci but also in a few GBS isolates [6] [7] [8] [9] . GBS have long been considered as uniformly penicillin-susceptible. Data regarding sporadic reports of isolates with phenotypically reduced susceptibility to penicillin have been difficult to interpret due to methodological concerns and differences in recommended susceptibility breakpoints. However, two recent studies have reported alterations in the penicillin binding protein 2X gene (pbp2x) in GBS leading to decreased penicillin susceptibility [10, 11] .
The antibiotic most often used for IAP in case of penicillin allergy is clindamycin [12] . Macrolides such as erythromycin, clarithromycin, and azithromycin have also been suggested as an alternative. The resistance rates for the macrolides-lincosamides-streptogramin B (MLS B ) group of antibiotics in GBS exhibit geographic differences and vary over time [13, 14] .
During 2005 a Swedish population-based study of GBS carriage in parturients and infants, and risk factors for colonization, was performed before a regular national IAP program had been implemented [15] . Of 1,569 mother/ infant pairs examined, the vaginal/rectal carriage rate of the mothers was 25.4%. With phenotypic antibiotic susceptibility tests, 5% of these isolates were found to be resistant to clindamycin and erythromycin. None of the isolates were resistant to penicillin G or showed high-level gentamicin resistance [15] . In the present study, 396 colonizing GBS were further examined for genetic resistance determinants of clindamycin, erythromycin, kanamycin, streptomycin, and tetracycline.
Materials and methods
The GBS isolates (n = 396) were from a nationwide surveillance study conducted in Sweden during 2005 [15] . The isolates were from the vagina/rectum from parturient women, and from surface cultures from 44 newborns in whom the cultures from the mothers were negative. Since the surface cultures of the infants were taken immediately after birth, the vaginal samples in these mothers were assumed to be false-negative. All GBS isolates were serotyped (types Ia, Ib, II-VIII) by co-agglutination (Essum AB, Umeå, Sweden). In non-typable isolates, a polymerase chain reaction (PCR)-based typing method was used [16] . By multilocus sequence typing (MLST), a serotype III lineage, CC17, containing sequence type 17 (ST17), associated with neonatal invasive infections, has been identified [17, 18] . The presence of the mobile genetic elements GBSi1 and IS1548 in serotype III isolates correlate with the phylogenetic lineages of clonal complexes 17 (CC17) and 19 (CC19), respectively [17] . Serotype III isolates of the study were further characterized by PCR for the presence of these mobile genetic elements. The serotypes of mother/infant pair isolates were congruent. The distribution of serotypes among the GBS was as follows: Ia 11%, Ib 13%, II 16%, III 24% (CC19 11%, CC17 11%), IV 15%, V 19%, VI 0.5%, VII 1%, and 0.5% non-typable. No serotype VIII isolates were found [15] .
Phenotypic antibiotic susceptibility testing
The isolates were cultured on blood agar plates containing Columbia agar base (Acumedia, Svenska Labfab, Ljusne, Sweden) and 5% defibrinated horse blood, and were identified as GBS as previously described [17] . Disk diffusion was performed on Iso-Sensitest Agar (ISA; Oxoid Ltd., Basingstoke, United Kingdom) with 5% defibrinated horse blood and 20 mg/L of nicotinamide adenine dinucleotide (NAD) with a semi-confluent inoculum according to the Swedish Reference Group of Antibiotics (SRGA, http://www.srga.org). Twenty-two isolates with MLS B resistance and 24 isolates with oxacillin inhibitions zones less than 18.5 mm on ISA-NAD agar were also tested with the disk diffusion method that, during 2010, will be recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST, http://www. eucast.org). In this method, streptococci are tested on Mueller-Hinton agar (MH) supplemented with 5% horse blood and 20 mg/L NAD with a confluent inoculum. Streptococcus pneumoniae ATCC 49619 was used for validation of the susceptibility tests. Screening for penicillin resistance was performed with 1-µg oxacillin disks and with the EUCAST method also with 30-µg ceftibuten disks. Minimum inhibitory concentrations (MICs) were tested with E-tests (AB Biodisk, Solna, Sweden). The plates were incubated for 18 h at 35°C in 5% CO 2 . To identify isolates with inducible MLS B resistance (iMLS B ), the double-disk diffusion test with an erythromycin disk and a clindamycin disk, both 15 μg, placed 25 mm apart was used. Flattening of the clindamycin growth inhibition zone indicate iMLS B . To screen for high-level aminoglycoside resistance, disks prepared with 1,000 μg kanamycin and streptomycin, respectively, were used [8] .
PCR amplification of resistance genes
The occurrence of the tetracycline resistance genes tet(O) and tet(M), the MLS B resistance genes erm(B), erm(A/TR), and mef(A), and the genes aad-6 and aphA-3 encoding aminoglycoside-modifying enzymes were determined with PCR according to Poyart et al. [19] . The aad-6 gene is also known as ant-6, and is coding for a streptomycin adenylyltransferase. DNA was extracted by the guanidium thiocyanate method [20] for the PCR reactions with the aad-6 and aphA-3 primers; for the other reactions, the samples were boiled in water for 10 min. The PCR mixtures of 50 μl contained 0.2 μM forward and reverse primers (DNA Technology A/S, Århus, Denmark), 1 U of AmpliTaq Gold (Applied Biosystems, Stockholm, Sweden), 0.2 mM of each deoxynucleoside triphosphate (Amersham Biosciences, Buckinghamshire, UK), 1.5 mM MgCl 2 , and 100 ng of template DNA in PCR buffer II with bovine serum albumin (Applied Biosystems). DNA amplification was carried out by initial denaturation at 95°C for 10 min and then cycling at 95°C for 1 min, 60°C for 30 s, and 72°C for 30 s for 35 cycles, with a final incubation at 72°C for 5 min in a DNA Engine PTC-200 (MJ Research Inc., Watertown, MA, USA). The amplicons were visualized by UV transillumination of ethidium bromide-stained 1.75% agarose gels. PCR products were sequenced with the BigDye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems) on an ABI 377 (ABI Prism Sequencer, Applied Biosystems).
Results
Phenotypic tetracycline resistance was identified in 313 isolates (79%). Every forth of these isolates were tested for the presence of tetO and tetM by PCR. In 89 of 94 isolates (94.7%), tetM was found and in 3 of 94 (3%), tetO was found. Neither tetO nor tetM could be identified in two of the 94 isolates (2%).
MLS B resistance was detected in 22 of the 396 isolates (5.5%). According to the breakpoints for erythromycin from the SRGA, beta-hemolytic streptococci with growthinhibition zones ≥ 23 mm are interpreted as susceptible and isolates with zones ≤19 mm as resistant. Nineteen GBS met the criteria for intermediate susceptibility or resistance with disk diffusion on ISA-NAD agar and had erythromycin MICs ≥1 mg/L, indicating resistance (Table 1) . No cutoff values for the disk diffusion have been determined by the EUCAST, but with the use of the EUCAST method, those 19 GBS had erythromycin inhibition zones <18 mm. In seven of these isolates, a flattened clindamycin inhibition zone indicated iMLS B . The erm (A/TR) gene was amplified in all iMLS B isolates and in three additional isolates, which lacked clindamycin inhibition zones. The ermB gene was identified in nine isolates (Table 1) . GBS with MLS B resistance caused by an active efflux mediated by mef genes have been described. The M-phenotypes of such isolates are erythromycin-resistant and clindamycin-susceptible without flattening of the clindamycin inhibition zone in the double diffusion test [21] . The mef(A) gene could not be identified in any of the isolates of this study, which is in agreement with a lack of isolates with the M-phenotype. Neither erm (A/TR), ermB, nor the mef(A) gene could be identified in three isolates that were susceptible to erythromycin but with clindamycin inhibition zones 1.5−0.5 mm below the present breakpoint for resistance set at 24 mm. The clindamycin MIC was 2 mg/L, which indicated resistance, while the erythromycin MICs were low ( Table 1) . Seven of the 64 serotype II isolates (11%), five of the 76 serotype V isolates (7%), and six of the 92 serotype III isolates (6.5%) exhibited MLS B resistance but only single isolates of serotype Ia, Ib, and IV. Four serotype V isolates harboring ermB, isolated from women from four different cities in Sweden, were the only isolates with MICs >256 mg/L for both erythromycin and clindamycin. Tetracycline resistance was found in 89% of the 44 serotype III isolates that harbored the GBSi1 intron, corresponding to CC17 [17] , but none of these isolates were erythromycin-or clindamycin-resistant.
All GBS had penicillin MICs ≤0.064 mg/L [15] . The distribution of the inhibition zones from the screening of penicillin resistance with 1-µg oxacillin disks suggested that all of the isolates could belong to the wild type population (Table 2 ). However, three GBS isolates gave inhibition zones ≤17 mm, the breakpoint set by the SRGA to guard for penicillin resistance in beta-hemolytic streptococci. The oxacillin MIC 90 for the GBS isolates of the study was 1 mg/L. The three isolates with oxacillin inhibitory zones repeatedly less than 17 mm (range 16.2-16.9 mm) were further tested and showed the following MICs: oxacillin 1 mg/L, penicillin G 0.032-0.064 mg/L, ampicillin 0.064-0.125 mg/L, cefuroxime 0.064 mg/L, cefotaxime 0.064-0.125 mg/L, imipenem 0.032-0.125 mg/L, and cefoxitin 2-4 mg/L. The identity of these isolates as GBS was confirmed with API-Strep (bioMériuex AB, Askim, Sweden). When tested with the EUCAST method, the inhibition zone ranges of the three isolates were 15.7-18.5 mm and 16.2-19.2 mm for oxacillin and ceftibuten. respectively, which is in agreement with the results of the other isolates tested (Table 2) .
In 28 isolates with inhibitory zones for gentamicin of ≤8 mm, the MICs were in the range 24-96 mg/L, i.e., 32-128 mg/l when the results are rounded up to the next highest twofold dilution, indicating that none of the isolates had high-level gentamicin resistance (http://www.srga.org). One of these 28 isolates, which had a gentamicin MIC of 64 mg/L, lacked an inhibition zone around the 1,000-μg kanamycin disk and harbored the aphA-3 gene. Four additional isolates, with gentamicin inhibition zones >8 mm, lacked inhibition zones around the highly loaded kanamycin disk and three of these also lacked inhibition zones around the 1,000-μg streptomycin disk (Fig. 1) . The kanamycin phosphorylase gene aphA-3 was present in all of the kanamycin-resistant isolates. In addition, the aad-6 gene, encoding a nucleotidyltransferase adenylylate The genes aad-6 and aphA-3 encode aminoglycoside-modifying enzymes
The genes erm(B), erm(A/TR), and mef(A) mediate resistance to the macrolides-lincosamides-streptogramin B group of antibiotics (Table 1) .
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Discussion
This study is, to our knowledge, the first report of high-level aminoglycoside resistance in GBS isolates from Scandinavia. Five of 396 GBS isolates (1.3%) from a nationwide study of colonizing GBS were kanamycin-and amikacin-resistant. Screening with kanamycin 1,000-μg disks enabled a rapid and easy detection of these isolates. The breakpoint for the susceptible isolates was originally proposed as 17 mm [8] .
However, the distribution of the GBS population from this study suggests that a lower breakpoint, possibly at 12 mm, would be more appropriate (Fig. 1) .
The kanamycin resistance gene aphA-3, present in these isolates, is in S. pneumoniae and Enterococcus faecalis, located on transposons and plasmids, but the exact genetic organization of the gene in these GBS isolates is not known. No isolates with high-level gentamicin resistance was found. Despite this, keeping the evolution in enterococci in mind, in which several aminoglycoside-modifying enzymes have been described [22] , an active surveillance on the aminoglycoside resistance in GBS is warranted. The first gentamicin high-level resistant (HLR) GBS, strain Table 2 Distribution of penicillin MICs by zone diameter for oxacillin using ISA-NAD with semiconfluent inoculum and for oxacillin and ceftibuten on MH-NAD with confluent inoculum B128, was described in France in 1990 [6] . The gene of the bifunctional aminoglycoside-modifying enzyme Aac(6′)-Aph (2″) that mediates resistance to gentamicin and all other aminoglycosides besides streptomycin, as well as homologs to aphA-3 and aad-6 genes, was later identified in B128 [9] . The aminoglycoside-resistant determinants were carried by the transposon Tn3706 located on the chromosome. Tn3706 could be transposed from its chromosomal location onto the plasmid IP501, a conjugative multiple antibiotic resistance plasmid that can be transferred and stably maintained in a variety of Gram-positive genera, including GBS [23] . However, the transposition led to a structural instability of the plasmid and the authors concluded that pIP501-like plasmids probably do not constitute appropriate vectors for the dissemination of gentamicin HLR in GBS. The clinical impact of HLR aminoglycoside resistance is a loss of the synergistic bactericidal effect achieved in conjunction with cell-wall-active antibiotics such as penicillin, which will compromise the effectiveness of therapy [5] . The combination of a cell-wall-active antibiotic and an aminoglycoside has been shown to greatly enhance the killing of GBS in vitro [5, 24] . Penicillin is the main choice for prophylaxis and therapy of GBS infections. The methodology used for the antibiotic susceptibility test is of vital importance when resistance data are interpreted. An additional important factor for the comparison of susceptibility among isolates is the breakpoints set for the classification of isolates. Screening for penicillin resistance with 1-μg oxacillin disks is recommended in S. pneumoniae and group A, B, C, and G streptococci by the SRGA. The breakpoint to guard for penicillin resistance is, at present, set at 17 mm. However, compared to the population distributions seen in pneumococci and group A, C, and G streptococci, with a majority of isolates with oxacillin inhibition zones of 27-28 mm (http://www.srga. org), the GBS of this study exhibited inhibition zones with a mean zone size of 20 mm (Table 2 ). This is in agreement with the data presented by Baker et al. almost 30 years ago, which showed that higher penicillin concentrations were needed for the growth inhibition and killing of GBS than for group A streptococci [5] . The oxacillin breakpoint of 17 mm divides what seems to be a susceptible (native) GBS population and, possibly, a breakpoint of 14 or 15 mm could be more suited for GBS. The results of the oxacillin screening according to the EUCAST method were in agreement with that suggestion. Recently, high sensitivity and specificity for the detection of reduced penicillin susceptibility in GBS was reported with a provisional cutoff value of 20 mm for ceftibuten in disk diffusion [25] . The tests were performed in accordance with the recommendation from the American Clinical and Laboratory Standards Institute (CLSI). From the results of our study, a ceftibuten breakpoint for susceptibility ≥ 15-16 mm seems to be more appropriate, a discrepancy possibly caused by the differences in the methods used. However, studies on the alteration of Pbp genes in relation to penicillin susceptibility are needed to fully evaluate the isolates with smaller inhibition zones.
During 2008, a risk-based program for IAP has been recommended by the National Board of Health in Sweden. Since this will lead to increased antibiotic use in the future, it is of importance to follow the epidemiology of antibiotic resistance in GBS to be able to give guidance for the prophylaxis used. This is especially important when a riskbased IAP program is used, since no individual GBS isolates are cultured for examination of the antibiotic susceptibility in this regime. The overall degree of antibiotic resistance in the Swedish colonizing GBS isolates was low, with the exception for 79% resistance against tetracycline. Only 5% of the GBS were resistant to clindamycin, which can be compared to MLS B resistance rates of around 15% in several European and Australian reports [18, 26] and 5-32% in the American continent [8, 27] .
An increased degree of MLS B resistance in serotype V isolates has been described [19, 26] . This has also been shown in recent Swedish and Norwegian studies of invasive GBS isolates [28, 29] . However, in this nationwide collection of colonizing GBS from parturient women, no serotype dominated among the clindamycin-and/or erythromycin-resistant isolates. Whether the high level of MLS B resistance found in the four serotype V isolates that carried the ermB gene indicate that they have an additional resistance mechanism has to be further evaluated.
The serotype III lineage, CC17, containing sequence type 17 (ST17), is strongly associated with neonatal invasive infections [17, 18] . In a recent study, serotype III isolates of ST17 were shown to carry less antibiotic resistance genes than the other GBS serotypes [14] . The lack of MLS B resistance in this lineage was corroborated in our study.
Here, we provide a baseline description of resistance levels and resistance genes present among colonizing GBS in Sweden before the implementation of a novel prophylactic regiment that will increase the use of intrapartum antibiotics. This kind of information will be useful in future evaluations of changes of resistance in GBS. We also suggest that a change of breakpoints for GBS oxacillin susceptibility tests should be considered. The results of this study partially disagree with some previous studies. We found no particular serotype to dominate among the MLS B -resistant isolates. In contrast, other studies, in particular those that have included invasive isolates [14, 27, 28] , indicate serotype V to be predominant among the MLS B -resistant GBS. In Norway, an increase in fatality rate among neonates with GBS infection has been observed, which coincided with an increase in MLS B resistance, predominantly in serotype V isolates [29] . A possible explanation for the discrepancy between our study and others is that a clonal dissemination of MLS Bresistant serotype V strains account for the increase among the invasive cases. We conclude that, in this Swedish colonizing material, serotype V is a poor predictor of antibiotic resistance. However, the occurrence of high-level erythromycin and clindamycin resistance found in all of the four serotype V isolates containing the ermB gene merits further examination. In summary, among Swedish colonizing GBS isolates, 5% MLS B resistance and 1.3% aminoglycoside resistance was found among the evenly distributed serotypes Ia to V.
